본문 바로가기

Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
AMERICAN JOURNAL OF KIDNEY DISEASES78(4) · pp.550 · 2021
피인용
Web of Science 33Scopus 41
FWCI (Scopus)
2.25
JCR IF
JCR 2020 8.86
ISSN
0272-6386

저자

  1. 이하린제1저자Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan, South Korea
  2. Berenger, BrendanUniv Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
  3. Mehta, Ravindra L.교신저자Univ Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
  4. Macedo, EtienneUniv Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA

초록

Objective: Regional citrate anticoagulation (RCA) is the preferred anticoagulation method for continuous kidney replacement therapy (CKRT) recommended by KDIGO. Limited availability of calcium-free solutions often imposes challenges to the implementation of RCA for CKRT (RCA-CKRT). The principal purpose of this study was to characterize the outcomes of RCA-CKRT using calcium-containing solutions. Study Design: Retrospective cohort study. Setting & Participants: We evaluated the safety and efficacy of RCA-CKRT with calcium-containing dialysate and replacement fluid used for 128 patients. A total of 571 filters and 1,227 days of CKRT were analyzed. Exposures: Liver disease, sepsis in the absence of liver disease, and sepsis with liver disease. Outcomes: Filter life and metabolic complications per 100 CKRT days. Analytical Approach: Linear mixed-effects model and generalized linear mixed-effects models. Results: The majority of patients were male (91; 71.1%), 32 (25%) had liver disease, and 29 (22.7%) had sepsis without liver disease. Median filter life was 50.0 (interquartile range, 22.0-118.0) hours, with a maximum of 322 hours, and was significantly lower (33.5 [interquartile range, 17.5-60.5] h) in patients with liver disease. Calcium-containing replacement solutions were used in 41.6% of all CKRT hours and reduced intravenous calcium requirements by 31.7%. Hypocalcemia (ionized calcium <0.85 mmol/L) and hypercalcemia (total calcium >10.6 mg/dL) were observed in 6.0 and 6.7 per 100 CKRT days, respectively. Citrate accumulation was observed in 13.3% of all patients and was associated with metabolic acidosis in 3.9%, which was not significantly different in patients with liver disease (9.3%; P = 0.2). Limitations: Lack of control groups that used calcium-free dialysate and replacement solutions with RCA-CKRT. Possible overestimation of filter life from incomplete data on cause of filter failure. Conclusions: Our study suggests that RCA-CKRT with calcium-containing solutions is feasible and safe in critically ill patients, including those with sepsis and liver disease.

키워드

CONTINUOUS RENAL REPLACEMENTSYSTEMIC HEPARIN ANTICOAGULATIONCRITICALLY-ILL PATIENTSCARE

식별자

Scopus EID
2-s2.0-85109021999
WoS UID
000702512700014